Related Experiment Video
Updated: May 24, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Rituximab therapy for connective tissue disease-associated interstitial lung disease: a systematic review and
Jiaqi Zhang1,2, Yanjun Wan1,3, Liheng Liu1,3
1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1, Xian Nong Tan Street, Xicheng District, Beijing 100050, China.
Background:
Rituximab (RTX) is utilized for treating connective tissue disease-associated interstitial lung disease (CTD-ILD) by eliminating pathogenic B cells, yet its clinical benefit remains debated. This study evaluates RTX's efficacy and safety in CTD-ILD.
Methods:
A literature search was conducted in PubMed, Embase, and Cochrane Library for studies on RTX in CTD-ILD up to May 24, 2024. The Joanna Briggs Institute checklist assessed study quality. Changes in forced vital capacity (FVC%) and diffusing capacity of the lungs for carbon monoxide (DLCO%) before and after RTX use were compared, and analyzed between RTX and control groups.
Results:
1052 CTD-ILD patients from 40 studies were analyzed. RTX significantly improved FVC% (WMD = 7.10, 95% CI = 4.58-9.62, P < 0.05) and DLCO% (WMD = 5.26, 95% CI = 2.86-7.65, P < 0.01), and reduced the modified Rodnan skin score (mRSS) (WMD = -6.58, 95% CI = -8.27 to -4.89, P < 0.01) and prednisone dose (WMD = -6.94, 95% CI = -11.96 to -1.92, P < 0.01). Among RTX-treated patients, 30.3% improved, 45.3% remained stable, and 10.0% progressed. Adverse effects included infection (22.4%), hospitalization (6.7%), and mortality (5.0%).
Conclusions:
RTX significantly enhances lung function in CTD-ILD patients, as shown in this systematic review and meta-analysis.
Systematic Review Registration:
PROSPERO, identifier CRD42024520084.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pneumothorax-II
Clinical Manifestations:
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...